DYADIC INTERNATIONAL INC (DYAI): Results of Operations and Financial Condition
DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, o
How this was made
The 30-second read
Why it matters
The disclosure updates key financial line items (cash, revenue, cost of revenue, operating loss) and adds operational milestones (product shipments, OEM distribution progress, and C1 platform productivity improvement), which can shift expectations for commercialization pace and burn rate.
Market read
Traders can use the cash and loss trajectory plus the specific commercialization and productivity milestones to reprice near-term risk and the narrative heading into the scheduled earnings call.
What to watch
Cash decreased materially versus year-end, and cost of revenue rose sharply due to grant-related costs; traders may underweight how these dynamics affect runway and near-term profitability.
DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS
Revenue decreased 0.6%, cost of revenue increased 60.4%, loss from operations increased 18.8%, and cash, cash equivalents, restricted cash, and investment-grade securities declined versus December 31, 2025. The company also disclosed substantial doubt about its ability to continue as a going concern for the 12 months following June 30, 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $961,138 | – | decrease of $5,492 or 0.6% |
| Total cost of revenueGAAP | $984,165 | – | increase of $370,574 or 60.4% |
| Research and development expensesGAAP | $332,621 | – | decrease of $296,758 or 47.2% |
| General and administrative expensesGAAP | $1,689,863 | – | increase of $253,233 or 17.6% |
| Loss from operationsGAAP | $2,054,204 | – | increase of $325,136 or 18.8% |
| Net lossGAAP | $2,123,884 | – | – |
| Net loss per shareGAAP | $(0.06) per share | – | – |
| Cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interestother | $4,794,798 | – | – |
What drove it
- Revenue was affected by a $89,563 decrease in research and development revenue resulting from the reduction in the numbers and size of collaboration activities and the absence of a $250,000 milestone revenue recorded in 2025.
- A $334,071 increase in grant revenue from activities under the CEPI and Gates Foundation grants partially offset the research and development revenue decline and absent milestone revenue.
- Cost of revenue increased due to a $395,709 increase in cost of grant revenue from activities under the CEPI and Gates Foundation grants, partially offset by a $25,135 decrease in the cost of research and development revenue.
- Research and development expenses declined due to reduction in the number of active internal research initiatives.
- General and administrative expenses increased due to higher rebranding and business development expenses of $322,638, increased legal and accounting expenses of $115,836, and other expenses of $43,639, partially offset by a decrease in share-based compensation expenses of $196,408 and incentives of $32,472.
- Pilot-scale process improvements increased recombinant human transferrin productivity by approximately 80%.
- The company initiated Q2 shipments to IBT Bioservices and reported commercialization activity or initial orders with Proliant Health & Biologicals, Fermbox Bio, and Inzymes.
Concerns
- Total cost of revenue exceeded total revenue for the three months ended June 30, 2026.
- Loss from operations increased, driven largely by higher total cost of revenue and higher general and administrative expenses.
- The company disclosed a history of net losses and management's conclusion that there is substantial doubt about its ability to continue as a going concern for the 12 months following June 30, 2026.
- Cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interest, were lower than at December 31, 2025.
- Commercial sales are described as product shipments, pilot sales, initial orders, and initial commercial sales, while the reported revenue mix includes research and development and grant activity.
What to watch
- Progress from product shipments directly and through distribution partners, including IBT Bioservices qualification and commercialization across its global life-science customer network.
- Commercialization of Albufree™ DX and planned expansion of the Albufree™ portfolio, which the company states positions it for future royalties.
- Scale-up activities with BRIG BIO for recombinant bovine alpha-lactalbumin and execution under the additional development and commercialization agreement disclosed subsequent to quarter-end.
- Delivery of C1-produced material to support initiation of preclinical studies with one or both Gates Foundation-funded RSV and malaria monoclonal antibody programs.
- Further evidence that productivity improvements and commercial launches translate into reported revenue while cost of revenue and general and administrative expenses are managed.
- Capital needs and any action to mitigate the disclosed going-concern risk.
Balance sheet and cash flow
- As of June 30, 2026, cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interest, were $4,794,798 compared to $8,587,289 as of December 31, 2025.
Analysis
Dyadic reported total revenue of $961,138 for the three months ended June 30, 2026, a decrease of $5,492 or 0.6% from $966,630 in the prior-year period. The revenue outcome reflected a $89,563 decrease in research and development revenue and the absence of a $250,000 milestone revenue recorded in 2025. A $334,071 increase in CEPI and Gates Foundation grant revenue partially offset those items. Operationally, the company described expanding product shipments, pilot sales, OEM distribution activity, and early commercialization across life-science, food and nutrition, and bioindustrial programs.
The cost structure worsened during the quarter. Total cost of revenue rose $370,574 or 60.4% to $984,165, with a $395,709 increase in grant-related costs partially offset by a $25,135 decrease in research and development revenue costs. Cost of revenue was higher than total revenue. Research and development expenses fell $296,758 or 47.2% to $332,621 because of fewer active internal research initiatives, but this reduction did not offset the increase in cost of revenue and general and administrative spending.
General and administrative expenses increased $253,233 or 17.6% to $1,689,863. The company attributed the increase to rebranding and business development, legal and accounting, and other expenses, partly offset by lower share-based compensation and incentives. Consequently, loss from operations increased $325,136 or 18.8% to $2,054,204, while net loss was $2,123,884, compared with $1,793,774 a year earlier. Net loss per share was $(0.06) per share in both periods.
Commercial progress centered on recombinant protein shipments, Proliant's commercialization of Albufree™ DX, scaled commercialization and initial orders at Fermbox Bio, and initial commercial sales at Inzymes. The company also reported that pilot-scale process improvements increased recombinant human transferrin productivity by approximately 80%. These developments support the stated commercialization strategy, but the release does not provide product-level revenue, partner revenue, royalty revenue, or segment revenue that would quantify their current contribution.
Liquidity remains the central financial issue. Cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including accrued interest, were $4,794,798 as of June 30, 2026, compared with $8,587,289 as of December 31, 2025. The release explicitly cites management's conclusion that substantial doubt exists about the company's ability to continue as a going concern for the 12 months following June 30, 2026. No forward financial guidance was provided, leaving commercialization conversion, grant-related costs, spending discipline, and financing actions as the principal items to monitor.
Management, verbatim
Our strong second-quarter performance underscores Dyadic’s ongoing transformation into a commercial-stage biotechnology leader.
Joe Hazelton, President and COO
We are driving commercial launches and sales of recombinant proteins, securing recurring revenue through strategic partners, distribution and optimizing manufacturing yields across life sciences, food and nutrition, and bioindustrial markets.
Joe Hazelton, President and COO
Not in the filing
stated, not guessed- Gross profit and gross margin
- Non-GAAP revenue, earnings, operating income, net income, EPS, or other non-GAAP measures
- Reportable segment revenue and segment profitability
- Prior-quarter revenue, expenses, losses, EPS, and cash-flow comparisons
- Operating cash flow
- Free cash flow
- Debt and other balance-sheet liabilities
- Capital returns, including share repurchases and dividends
- Forward financial guidance for revenue, gross margin, operating expenses, tax rate, earnings, cash flow, or capital spending
- Prior outlook for comparison
- Product-level, partner-level, royalty, licensing, and grant revenue amounts
- Net-loss year-over-year percentage change
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Dyadic filed an 8-K (Item 2.02) with Exhibit 99.1 announcing second-quarter 2026 financial results and commercialization updates, and it scheduled an earnings call for Aug 12, 2026.
Ticker impact
Dyadic reported Q2 2026 results and highlighted commercialization progress plus C1 biomanufacturing platform expansion in an 8-K.
Likely volatility around the earnings call, with direction dependent on whether investors focus on commercialization momentum versus cash burn and higher cost of revenue.
This is a primary earnings-style disclosure (8-K with Exhibit 99.1) including cash balance, revenue, cost of revenue, and operating loss, plus specific commercialization milestones and platform productivity improvements.
Market effects
Adds datapoints on commercialization traction and manufacturing productivity for animal-free protein and enzyme platforms, relevant to biotech platform narratives.
Limited, company-specific biotech update from Jupiter, Florida.
Moderate, given mention of international partners and global health programs (Gates Foundation, CEPI, NIAID, FBS ecosystem).
Counterpoint
Investors may discount commercialization claims if revenue remains small and operating loss worsens, focusing instead on cash drawdown and cost structure.
Key entities
- companyDyadic International, Inc.
NASDAQ-listed biotechnology company producing precision-engineered, animal-free proteins and enzymes, reporting Q2 2026 results and commercialization progress.
- personJoe Hazelton
President and COO quoted on commercialization momentum and C1 platform validation.
